FUJIFILM Diosynth Biotechnologies Releases Mammalian Expression Platform

October 9, 2014
BioPharm International Editors

The Apollo platform can be used throughout a product?s entire lifecycle.

FUJIFILM Diosynth Biotechnologies announced the release of “Apollo”, a new technology solution for the manufacture of therapeutic proteins. The platform, designed to create a robust cell line to be used for preclinical material through to commercial production, will feature a new Chinese hamster ovary DG44-derived cell line, a novel expression vector, a cell-line development process, and optimized media and feed components.

The Apollo platform allows production of a representative material within 10 weeks of receiving a gene sequence and enables a clonal cell line within 25 weeks from transfection. The expression system complements FUJIFILM’s pAVEway advanced protein expression for microbial-based biopharmaceuticals.

The Apollo system offers a fully functional ‘gene to GMP’ service for clients, according to Mark Carver, MD, senior vice-president of research, development, and innovation at FUJIFILM Diosynth Biotechnologies. Carter believes the addition of Apollo to the company’s product profile enhances its predictive screening and high throughput approach capabilities. “We believe the platform has great potential—early media optimization indicates we can exceed 5g/L,” said Carter in a press release.

Source:
FUJIFILM Diosynth Biotechnologies